| Margaret Behr, | |
|
20630 Route 19, Suite 101, Cranberry Township, PA 16066-6021 | |
| (724) 779-2273 | |
| Not Available |
| Full Name | Margaret Behr |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 20630 Route 19, Cranberry Township, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194044917 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS016254 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Upmc Passavant | Pittsburgh, PA | Hospital |
| Magee Womens Hospital Of Upmc Health System | Pittsburgh, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upmc Community Medicine Inc | 2062318975 | 690 |
News Archive
It is not levels of underage drinking, but early signs of antisocial behaviour that best predict future alcohol-related trouble and continued alcohol use by young people.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis, a rare and often fatal lung disease whose cause is unknown.
Patients who had their wisdom teeth extracted had improved tasting abilities decades after having the surgery, a new Penn Medicine study published in the journal Chemical Senses found.
› Verified 1 days ago
| Entity Name | Upmc Community Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558976092 PECOS PAC ID: 2062318975 Enrollment ID: O20040217000388 |
News Archive
It is not levels of underage drinking, but early signs of antisocial behaviour that best predict future alcohol-related trouble and continued alcohol use by young people.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis, a rare and often fatal lung disease whose cause is unknown.
Patients who had their wisdom teeth extracted had improved tasting abilities decades after having the surgery, a new Penn Medicine study published in the journal Chemical Senses found.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Margaret Behr, 20630 Route 19, Suite 101, Cranberry Township, PA 16066-6021 Ph: () - | Margaret Behr, 20630 Route 19, Suite 101, Cranberry Township, PA 16066-6021 Ph: (724) 779-2273 |
News Archive
It is not levels of underage drinking, but early signs of antisocial behaviour that best predict future alcohol-related trouble and continued alcohol use by young people.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis, a rare and often fatal lung disease whose cause is unknown.
Patients who had their wisdom teeth extracted had improved tasting abilities decades after having the surgery, a new Penn Medicine study published in the journal Chemical Senses found.
› Verified 1 days ago
Dr. Hilary A Stroud, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 20397 Route 19, Two Landmark North, Cranberry Township, PA 16066 Phone: 724-772-3300 Fax: 724-772-3360 | |
Sarah Brighthaupt Wittman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 20397 Route 19 Ste 330, Cranberry Township, PA 16066 Phone: 724-772-3300 Fax: 724-772-3360 | |
Nicolas Evan Merzlak, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 20397 Route 19 Ste 330, Cranberry Township, PA 16066 Phone: 724-772-3300 Fax: 724-772-3360 | |
Kady Miletti, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 20397 Route 19 Ste 330, Cranberry Township, PA 16066 Phone: 724-722-3300 Fax: 724-772-3360 | |
David M Swan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 20397 Route 19 Ste 330, Cranberry Township, PA 16066 Phone: 724-772-3300 Fax: 724-772-3360 | |
Kirsten Lin, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 20397 Route 19, Cranberry Township, PA 16066 Phone: 724-772-3300 Fax: 724-772-3360 |